X-Chem will screen its DNA-encoded libraries to discover novel antivirals for Gilead.
Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
CRO lobby group ACRO wants the government to drill down into what tax reform can mean for research.
Quotient Clinical has rebranded as Quotient Sciences, and right after that, made its third purchase this year.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.
Part of an international initiative, a pan-European observational study aims to improve clinical care of traumatic brain injury.
About a year after QuintilesIMS was born from a megamerger between Quintiles and IMS Health, the contract research giant has decided to turn the page.
Bioclinica is looking to broaden its reach with the purchase of MDDX Research & Informatics.